CSF1R and breast cancer: We tested the performance of this MIMA prediction in a systemic treatment of the EMT6 breast cancer model, by treating mice bearing tumors orthotopically implanted into the mammary fat pads of immunocompetent syngeneic mice with intraperitoneal injections of palbociclib, an anti-CSF1R antibody monotherapy and a combination of the two.